Evidence map›Paper›PMID 42563688›Full record

ReviewInternational journal of molecular medicine2026

Contribution of p38 MAPK in liver fibrosis: An overview of mechanisms, signaling pathways, and therapeutic targets (Review).

Xueqin Yang, Huarong Li, Hao Ye, Ting Wu, Fangyun Xu, Chao Hu, Chunlei Yu, Pian Ye

Abstract readReview
In one paragraph

Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueqin Yang *Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Huarong Li *Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Hao YeDepartment of Infectious Diseases, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, Hubei 431899, P.R. China.
Ting WuDepartment of Infectious Diseases, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, Hubei 431899, P.R. China.
Fangyun XuDepartment of Infectious Diseases, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, Hubei 431899, P.R. China.
Chao HuDepartment of Infectious Diseases, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, Hubei 431899, P.R. China.
Chunlei YuDepartment of Infectious Diseases, Jingshan Union Hospital, Union Hospital, Huazhong University of Science and Technology, Jingshan, Hubei 431899, P.R. China.
Pian YeDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is a progressive pathological state characterized by aberrant accumulation of extracellular matrix (ECM), predominantly mediated by activation of hepatic stellate cells (HSCs). If left untreated, this condition can progress to cirrhosis, liver failure, and even hepatocellular carcinoma. As a pivotal constituent of the mitogen‑activated protein kinase (MAPK) superfamily, p38 MAPK orchestrates critical cellular processes, including proliferation, differentiation, and stress responses. The p38 MAPK signaling cascade has been identified as a central orchestrator of the pathogenic mechanisms underlying liver fibrosis, mediating key processes such as HSC activation, ECM remodeling, inflammation, oxidative stress, and apoptosis. Developing novel antifibrotic therapies hinges on a comprehensive elucidation of the functional roles and regulatory mechanisms governing p38 MAPK. The present review aims to provide an exhaustive synthesis of the mechanisms and signaling networks by which p38 MAPK contributes to liver fibrogenesis. Its roles in HSC transformation, interactions with other critical pathways (including NF‑κB, TGF‑β/Smad, JAK/STAT, and PI3K/Akt), and involvement in inflammatory and oxidative responses are explored. Furthermore, the therapeutic potential of targeting p38 MAPK is highlighted by preclinical evidence from pharmacological inhibitors, natural compounds, and traditional medicines that modulate this pathway to attenuate fibrosis. In conclusion, while p38 MAPK represents a promising therapeutic target for liver fibrosis, future research should focus on developing isoform‑specific inhibitors, understanding context‑dependent signaling outcomes, and designing combination therapies to enhance efficacy and minimize off‑target effects. This synthesis aims to bridge current molecular insights with clinical translation, offering a roadmap for future antifibrotic drug development.

Indexed as

Liver Cirrhosisp38 Mitogen-Activated Protein KinasesSignal TransductionAnimalsHepatic Stellate CellsHumansMolecular Targeted Therapyp38 Mitogen-Activated Protein KinasesECMHSCsliver fibrosismechanismsp38 MAPKsignaling pathwaystherapeutic targets

Identifiers

PMID42563688
PMCPMC13451051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.